OA10221A - Oligonucléotides pour inhiber le rôle des isoprényl protéine transférases - Google Patents

Oligonucléotides pour inhiber le rôle des isoprényl protéine transférases Download PDF

Info

Publication number
OA10221A
OA10221A OA60679A OA60679A OA10221A OA 10221 A OA10221 A OA 10221A OA 60679 A OA60679 A OA 60679A OA 60679 A OA60679 A OA 60679A OA 10221 A OA10221 A OA 10221A
Authority
OA
OAPI
Prior art keywords
seq
sequence
oligonucleotides
nucleotide
type
Prior art date
Application number
OA60679A
Other languages
English (en)
French (fr)
Inventor
Colote Soudhir
Pirotzky Eduardo
Original Assignee
Sod Conseils Rech Applic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sod Conseils Rech Applic filed Critical Sod Conseils Rech Applic
Publication of OA10221A publication Critical patent/OA10221A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y205/00—Transferases transferring alkyl or aryl groups, other than methyl groups (2.5)
    • C12Y205/01—Transferases transferring alkyl or aryl groups, other than methyl groups (2.5) transferring alkyl or aryl groups, other than methyl groups (2.5.1)
    • C12Y205/01029—Geranylgeranyl diphosphate synthase (2.5.1.29)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Plant Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
OA60679A 1994-06-29 1995-06-29 Oligonucléotides pour inhiber le rôle des isoprényl protéine transférases OA10221A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB9413035A GB9413035D0 (en) 1994-06-29 1994-06-29 Antisense oligonucleeotides

Publications (1)

Publication Number Publication Date
OA10221A true OA10221A (fr) 1997-09-19

Family

ID=10757497

Family Applications (1)

Application Number Title Priority Date Filing Date
OA60679A OA10221A (fr) 1994-06-29 1995-06-29 Oligonucléotides pour inhiber le rôle des isoprényl protéine transférases

Country Status (25)

Country Link
US (1) US5856461A (sv)
EP (1) EP0692535A1 (sv)
JP (1) JPH0851985A (sv)
KR (1) KR960000914A (sv)
CN (1) CN1124142A (sv)
AU (1) AU689887B2 (sv)
BR (1) BR9503015A (sv)
CA (1) CA2152233A1 (sv)
CZ (1) CZ291496B6 (sv)
DZ (1) DZ1903A1 (sv)
FI (1) FI953170A (sv)
FR (2) FR2721827A1 (sv)
GB (2) GB9413035D0 (sv)
HU (1) HU219823B (sv)
IE (1) IE950477A1 (sv)
MA (1) MA23595A1 (sv)
NO (1) NO952601L (sv)
NZ (1) NZ272398A (sv)
OA (1) OA10221A (sv)
PL (1) PL309384A1 (sv)
RU (1) RU2112766C1 (sv)
SE (1) SE9502259L (sv)
SK (1) SK83895A3 (sv)
TN (1) TNSN95068A1 (sv)
ZA (1) ZA955288B (sv)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2226623A1 (en) * 1995-07-13 1997-01-30 University Of Cincinnati Compounds useful in the treatment of neurofibromatosis
CN1301731A (zh) * 1999-12-24 2001-07-04 上海博德基因开发有限公司 一种新的多肽——多异戊二烯基合成酶蛋白9和编码这种多肽的多核苷酸
US20030157598A1 (en) * 2000-12-07 2003-08-21 Ramanathan Chandra S. Novel human G-protein coupled receptor, HGPRBMY23, expressed highly in kidney
US20030212017A1 (en) * 2002-05-10 2003-11-13 Isis Pharmaceuticals Inc. Antisense modulation of farnesyl transferase beta subunit expression
US7507808B2 (en) * 2002-12-12 2009-03-24 Isis Pharmaceuticals, Inc. Modulation of endothelial lipase expression
DK3342425T3 (da) 2003-09-09 2020-03-16 Geron Corp Modificerede oligonukleotider til inhibering af telomerase
US8785409B2 (en) * 2007-01-30 2014-07-22 Geron Corporation Compounds having anti-adhesive effects on cancer cells
JOP20200257A1 (ar) 2014-05-01 2017-06-16 Geron Corp تركيبات أوليجو نوكليوتيد وطرق لتحضيرها

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4571421A (en) * 1979-11-05 1986-02-18 Genentech, Inc. Mammalian gene for microbial expression
US5004803A (en) * 1988-11-14 1991-04-02 Genetics Institute, Inc. Production of procoagulant proteins
US5420245A (en) * 1990-04-18 1995-05-30 Board Of Regents, The University Of Texas Tetrapeptide-based inhibitors of farnesyl transferase
US5185248A (en) * 1990-05-08 1993-02-09 E. R. Squibb & Sons, Inc. Farnesyl-protein transferase assay for identifying compounds that block neoplastic transformation
KR100242671B1 (ko) * 1991-03-07 2000-03-02 고돈 에릭 유전학적으로 처리한 백신 균주
NZ244820A (en) * 1991-10-25 1994-01-26 Isis Pharmaceuticals Inc Oligonucleotide inhibitor of epstein-barr virus.
US5348853A (en) * 1991-12-16 1994-09-20 Biotronics Corporation Method for reducing non-specific priming in DNA amplification
US5585479A (en) * 1992-07-24 1996-12-17 The United States Of America As Represented By The Secretary Of The Navy Antisense oligonucleotides directed against human ELAM-I RNA

Also Published As

Publication number Publication date
SK83895A3 (en) 1996-05-08
FR2721930B1 (fr) 1997-01-03
FI953170A (sv) 1995-12-30
CZ291496B6 (cs) 2003-03-12
HU219823B (hu) 2001-08-28
US5856461A (en) 1999-01-05
FR2721827A1 (fr) 1996-01-05
FI953170A0 (sv) 1995-06-27
RU2112766C1 (ru) 1998-06-10
KR960000914A (ko) 1996-01-25
HUT72133A (en) 1996-03-28
GB2290791B (en) 1998-08-05
AU2329995A (en) 1996-01-11
TNSN95068A1 (fr) 1996-02-06
EP0692535A1 (fr) 1996-01-17
NZ272398A (en) 1996-04-26
MA23595A1 (fr) 1995-12-31
SE9502259L (sv) 1995-12-30
AU689887B2 (en) 1998-04-09
GB2290791A (en) 1996-01-10
GB9413035D0 (en) 1994-08-17
SE9502259D0 (sv) 1995-06-21
BR9503015A (pt) 1996-06-04
DZ1903A1 (fr) 2002-02-17
FR2721930A1 (fr) 1996-01-05
IE950477A1 (en) 1996-01-10
ZA955288B (en) 1996-01-31
CA2152233A1 (en) 1995-12-30
NO952601L (no) 1996-01-02
JPH0851985A (ja) 1996-02-27
HU9501913D0 (en) 1995-08-28
PL309384A1 (en) 1996-01-08
CZ168895A3 (en) 1996-05-15
RU95110774A (ru) 1997-04-20
GB9513246D0 (en) 1995-09-06
CN1124142A (zh) 1996-06-12
NO952601D0 (no) 1995-06-28

Similar Documents

Publication Publication Date Title
CA2222197A1 (fr) Oligonucleotides antisens pour bloquer la synthese du recepteur de l'ige
JP4643906B2 (ja) 遺伝子発現の標的化阻害のための合成二本鎖オリゴヌクレオチド
EP1807536B1 (fr) IDENTIFICATION ET UTILISATION DE miRNAs IMPLIQUES DANS LA DIFFERENCIATION DE CELLULES ISSUES D'UNE LEUCEMIE MYELOIDE
AU674158B2 (en) Hybrid oligonucleotide phosphorothioates
EP0736093B1 (en) ANTISENSE NUCLEIC ACIDS FOR THE PREVENTION AND TREATMENT OF DISORDERS IN WHICH EXPRESSION OF c-erbB-2 PLAYS A ROLL
JPH09507502A (ja) ｒａｆ遺伝子発現のアンチセンスオリゴヌクレオチド調節
JP2000509259A (ja) 血管内皮増殖因子（ＶＥｇＦ／ＶＰＦ）発現のアンチセンス阻害剤
JPH11501509A (ja) ｔ（１４：１８）転座を有する腫瘍細胞に関連するアンチセンス転写産物とこの腫瘍細胞の診断及び治療に有用なオリゴデオキシヌクレオチド
JPH10508760A (ja) ｒａｆ遺伝子発現のアンチセンスオリゴヌクレオチド調節
JPH08505397A (ja) 平滑筋細胞の増殖を調節するためのｃ‐ｍｙｃのアンチセンス阻害
EP3061824B1 (en) Organic compositions to treat beta-enac-related diseases
CA2795145A1 (en) Treatment of colony-stimulating factor 3 (csf3) related diseases by inhibition of natural antisense transcript to csf3
CA2882443A1 (en) Rnai probes targeting cancer-related proteins
WO1996029399A1 (fr) Oligonucleotides antisens pour inhiber le role de l'helicobacter pylori
OA10221A (fr) Oligonucléotides pour inhiber le rôle des isoprényl protéine transférases
JPH07508977A (ja) インターロイキン−１の阻害による細胞の過剰増殖の処置
EPA et al. Enhanced downregulation of the p75 nerve growth factor receptor by cholesteryl and bis-cholesteryl antisense oligonucleotides
KR102061924B1 (ko) Ｐ３２ 저해제를 포함하는 심혈관 질환 예방 또는 치료용 조성물
JP4690649B2 (ja) 標的化された遺伝子発現阻害のための新規なオリゴリボヌクレオチド誘導体
JP2000506866A (ja) アンギオテンシノゲンｍＲＮＡに標的化されたオリゴヌクレオチド
KR20010042796A (ko) 인테그린 αｖ-아단위 발현 억제를 위한 안티센스올리고뉴클레오티드
US20210214727A1 (en) Enhanced oligonucleotides for inhibiting scn9a expression
Pendergraff et al. Locked Nucleic Acid gapmers and conjugates induce potent silencing of ADAM33, an asthma-associated metalloprotease with nuclear-localized mRNA
TW202405174A (zh) 用於抑制超氧化物歧化酶1(SOD1)表現之RNAi藥劑、其組合物及使用方法
FR2834465A1 (fr) Compositions pour la vectorisation d'oligonucleotides a travers la barriere hematoencephalique et leur utilisation pour le traitement des maladies du systeme nerveux central